SPY продолжает рост

Ближайший уровень поддержки по SPY – 198.50 уровень сопротивления – 199.10



MUR покупка выше 68

APD смотрим на разворот вниз

EXP продажа при удержании 97

TRIP смотрим на покупку

XLNX покупка от 41

UIS покупка от 20

Gapping up/down: FB +9%, UA +5% and FFIV +2% after earnings, QRE +11% after M&A news, RKUS +2% after added to GS Conviction Buy list; ANGI -25% and GM -2% after earnings, SRPT -9% after terminating CSO, BA -1% after earnings

Gapping up
In reaction to strong earnings/guidance: VDSI +14.9%, LOGI +14.8%, QRE +11.3%, AGEN +9.8%, FB +9.2%, TDY +9%, FTNT +8.6%, SKX +8.4%, NOK +8.2%, UA +5.6%, EGHT +5.5%, HBI +5.2%, COG +4.7%, ORLY +4.4%, RJF +4%, PTEN +3.9%, ILMN +3.5%, JBLU +3.3%, NVEC +2.9%, POT +2.9%, INFN +2.8%, CRI +2.8%, UAL +2.2%, UAL +2.2%, FFIV +2%, IMAX +1.9%, SQNS +1.8%, MMM +1.8%, BMY +1.6%, HOT +1.5%, CAM +1.5%, CTXS +1.3%, ABC +1.3%, GILD +1.1%, NURO +1%.


M&A news: QRE +11.3% (to be acquired by Breitburn Energy Partners (BBEP)), ARIA +7.1% (attributed to a positive tweet that has since been deleted; Tweet was with regards to a SHPG for ARIA rumor).

Other news: APP +8.3% (disclosed details of new Board of Directors), DARA +8.1% (cont momentum), SPNC +7.4% (announces FDA clearance of peripheral laser atherectomy devices for in-stent restenosis ), TWTR +4.1% (following FB results), JMBA +3.8% (Engaged Capital disclosed 7.0% stake in SC 13D filing; believe the Issuer possesses multiple paths to value creation, expects to continue to have discussions with the Issuer's management), KNDI +2% (following yesterday's 12% decline), P +2% (following FB results), LNKD +1.3% (following FB results), FEYE +0.9% (on FTNT results), LL +0.9% (responded to lawsuit allegations, stating, «The allegations in this lawsuit concerning our product are simply flat-out false»)

Analyst comments: WIBC +3.4% (upgraded to Strong Buy from Outperform at Raymond James), RKUS +2.6% (added to Conviction Buy list at Goldman), UIS +1.4% (upgraded to Positive from Neutral at Susquehanna), ZFGN +0.6% (initiated with a Outperform at Leerink Partners)

Gapping down
In reaction to disappointing earnings/guidance: ANGI -25.1%, TRIP -10.1%, PLCM -5.3%, DNKN -5.1%, QCOM -4.4%, TQNT -4.3%, CRUS -4.3%, BBEP -3.1%, VAR -2.9%, GM -2.4%, MNRO -2.3%, ALXN -1.8%, DHI -1.7%, T -1.4%, ETFC -1.4%, TEX -1.4%, CAKE -1.3%, CAT -1.3%, TSCO -1.1%, SGMO -1%, TER -0.9%, BSX -0.9%, GPI -0.9%, CELG -0.8%, RDWR -0.6%.

M&A news: EGAS -3.2% (responds to press release issued by Algonquin Power & Utilities and reiterates rejection of their grossly inadequate, unsolicited offers), BBEP -3.1% (acquired QR Energy LP in a unit-for-unit exchange implying a transaction value of ~ $3.0 bln).

Other news: CALI -33.9% (co said it will vigorously oppose 'grossly unfair and damaging' plan by Depository Trust Company to impose 'global lock' on its securities), GPRC -13.2% (reported receipt of notice from DTC of plans to impose 'global lock' on its securities; company says DTC plans are 'unfair and unnecessarily damaging to current shareholders and is reviewing options'), SRPT -9.2% (discloses that Arthur Krieg, Senior Vice President and Chief Scientific Officer, was terminated from his position with the company), INCY -8.1% (also announces top-line results from RELIEF trial of ruxolitinib in patients with polycythemia vera; statistical significance not achieved for the primary endpoint of symptom control; positive trends in favor of ruxolitinib versus hydroxyurea observed), MHFI -7.6% (receives Wells Notice from SEC regarding S&P's rating of six commercial mortgage backed securities transactions in 2011), GOV -5.6% (prices 13.5 mln common shares at $23.50 per share), QUNR -1.9% (following TRIP results), INO -1.5% (files for $175 mln mixed securities shelf offering).